Citigroup Maintains Sell on Core Laboratories, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Scott Gruber maintains a 'Sell' rating on Core Laboratories (NYSE:CLB) and has lowered the price target from $21 to $20.
September 18, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup has maintained a 'Sell' rating on Core Laboratories and lowered the price target from $21 to $20.
The 'Sell' rating maintained by Citigroup and the lowering of the price target indicates a negative outlook for Core Laboratories. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100